Speaker(s): 

Timothy L. Lindemann, MD, Staff Member, Geisinger - has nothing to disclose.

T. Logan Lindemann, MD, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Ellen Penn, MD, Resident, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to:

1.   

• Discuss the features which define EGPA.
• Review the workup of patients suspected of EGPA
• Recognize and understand the various treatments indicated for the various phases of EGPA

2.

• Discuss the features which define MRONJ.
• Review the staging of MRONJ
• Recognize and understand the pathogenesis of MRONJ and risk factors associated with its development. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Aileen Wertz, MD; Kenneth Altman, MD, PhD; Vincent Desiato, DO; Curtis Gehman, PA-C; Michele Shulski, BSN, RN and Kathryn Kole, CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None